Mouse Disease Timelines

Timelines

t

Line # Onset Pronounced Experiment Mouse Model Phenotype Classification Sub phenotype Classification Phenotype location Phenotype Characteristic / Test Notes
1 4.5 wks 10-13 wks 10: 11353291 R6/2 Pathological/morphological aggregates brain/hippocampus DG NII DG, dentate gyrus; NII neuronal intranuclear inclusion; onset not well documented; immunogold anti-ubiquitin ab
2 11 wks n/d 5: 16127709 R6/2 behavior motor organism grip strength, forelimb
3 3 wks 5-7 wks 17: 15505789 R6/2 E-phys changes receptor/neurotransmitter responses brain/striatum/medium-sized spiny neurons Increased frequency of spontaneous GABAergic synaptic currents
4 n/d 11-15 wks 18: 15625098 R6/2 E-phys changes basic membrane properties brain/striatum/medium-sized spiny neurons reduced membrane capacitance
5 8-9 wks 9-13.5 wks 7: 10191337 R6/2 behavior motor organism footprint test Gait changes seen at 8.5 wks were similar to those seen at 13.5 wks.
6 7 wks 10-11 wks 23: 10575040 R6/2 behavior cognitive organism two-choice swim tank, acquisition (visual learning)
7 8.6 wks 12.9 wks 5: 16127709 R6/2 Pathological/morphological atrophy brain brain volume decrease, ventricular
8 8 wks 13-14 wks 24: 16111888 R6/2 behavior motor organism grip strength
9 8.6 wks 12.9 wks 5: 16127709 R6/2 Pathological/morphological atrophy brain brain volume decrease
10 12.9 wks n/d 5: 16127709 R6/2 Pathological/morphological neurodegeneration brain/striatum decrease in striatal neuronal area/number
11 6 wks 12 wks 15: 10196370 R6/2 Pathological/morphological atrophy heart atrophy
12 10.7-12.1 wks n/d 16: 11746372 R6/2 E-phys changes calcium channels brain/striatum/medium-sized spiny neurons reduced calcium current amplitude neurons from pre-symptomatic mice (5-6.5 wks) had slightly higher peak calcium currents
13 n/d 10 wks 10: 11353291 R6/2 Pathological/morphological aggregates brain/thalamus ENNI ENNI, extranuclear inclusion; immunogold anti-ubiquitin ab
14 8-12 wks n/d 1: 15579164 R6/2 E-phys changes Non-CNS changes neuromuscular junction increased mconotoxin resistance
15 6 wks 8 wks 15: 10196370 R6/2 Pathological/morphological aggregates kidney nuclear inclusions
16 4 wks 6-12 wks 6: 10369868 R6/2 Pathological/morphological aggregates brain/cortex NII NII, neuronal intranuclear inclusion; EM48 ab
17 6 wks n/d 5: 16127709 R6/2 behavior motor organism hindlimb clasping (dyskinesia)
18 8.6 wks n/d 21: 10533044 R6/2 E-phys changes receptor/neurotransmitter responses brain/striatum/medium-sized spiny neurons cell swelling in response to NMDA also observed depolarized RMP, but did not discuss age of onset
19 n/d 7-13 wks 10: 11353291 R6/2 Pathological/morphological aggregates brain/hippocampus CA3 ENNI ENNI, extranuclear inclusion; immunogold anti-ubiquitin ab
20 4 wks 6-12 wks 6: 10369868 R6/2 Pathological/morphological aggregates brain/striatum NII NII, neuronal intranuclear inclusion; EM48 ab
21 7 wks 8.5-12.5 wks 8: 10078572 R6/2 Pathological/morphological metabolic organism diabetes
22 5-7 wks 11-15 wks 19: 12574425 R6/2 E-phys changes action potential properties brain/striatum/medium-sized spiny neurons reduction in the frequency of spontaneous EPSC’s EPSP, excitatory postsynaptic potential
23 n/d 6 wks 22: 10829080 R6/2 E-phys changes receptor/neurotransmitter responses brain/striatum/medium-sized spiny neurons reduced dopaminergic modulation of GABAA current Lack of dopaminergic channel modulation was due to defects in the D1/cAMP/PKA/DARPP-32 signaling cascade.
24 8 wks 12-13 wks 7: 10191337 R6/2 behavior motor organism excessive grooming/ hyperactivity
25 5-7 wks 9-14 wks 17: 15505789 R6/2 E-phys changes basic membrane properties brain/striatum/medium-sized spiny neurons increased input resistance The change at 5-7 wks was observed, but not shown to be significant
26 n/d 7- 13 wks 10: 11353291 R6/2 Pathological/morphological aggregates brain/hippocampus CA1 ENNI ENNI, extranuclear inclusion; immunogold anti-ubiquitin ab
27 39 wks 52 wks 26: 12812983 YAC 128 Pathological/morphological atrophy brain brain weight loss 5% decrease in brain wt. at 9 mo, progressing to 10% at 12 mo.
28 n/d 12-13 wks 7: 10191337 R6/2 behavior motor organism abrupt shuddering moments
29 8 wks 12 wks 15: 10196370 R6/2 Pathological/morphological atrophy liver atrophy
30 4.3 wks 12.9 wks 5: 16127709 R6/2 Pathological/morphological atrophy brain brain weight loss
31 8 wks n/d 25: 16137562 R6/2 behavior motor organism decreased anxiety (light/dark box) Decreased anxiety was observed for both male and female mice, and may be a function of reduced activity at 8 wks.
32 5-6 wks 10+ wks 20: 10864968 R6/2 E-phys changes synaptic plasticity brain/hippocampus CA1 / reduced LTP LTP, long-term potentiation
33 6 wks 8 wks 15: 10196370 R6/2 Pathological/morphological aggregates pancreas nuclear inclusions
34 11-15 wks n/d 18: 15625098 R6/2 E-phys changes basic membrane properties brain/striatum/medium-sized spiny neurons decreased membrane time constants time constants were slightly shorter, but not significantly shorter than wt
35 8 wks n/d 23: 10575040 R6/2 behavior cognitive organism visual cliff avoidance (visual learning)
36 11.6-14.4 wks n/d 13: 11731527 R6/2 E-phys changes action potential properties brain/striatum/medium-sized spiny neurons decreased AP decay slopes
37 n/d 11-15 wks 18: 15625098 R6/2 E-phys changes potassium channels brain/striatum/medium-sized spiny neurons reduced inward potassium current density
38 6 wks 8 wks 15: 10196370 R6/2 Pathological/morphological aggregates adrenal glands nuclear inclusions
39 11.6-14.4 wks n/d 13: 11731527 R6/2 E-phys changes basic membrane properties brain/striatum/medium-sized spiny neurons depolarized RMPs RMP, resting membrane potentials
40 n/d 39 wks 26: 12812983 YAC 128 Pathological/morphological atrophy brain/striatum striatal volume A 15% decrease in striatal volume was observed at 9 mo. No decrease detected at 6 mo.
41 4-9 wks 14 wks 24: 16111888 R6/2 behavior motor organism decreased exploratory activity Activity, mobility, and rearing were measured using the AM1053 activity cage system
42 10 wks 13 wks 2: 8898202 R6/2 Pathological/morphological general organism survival A single mouse, with symptom onset at 4.5 wks died early at 6.5 wks
43 12.9 wks n/d 5: 16127709 R6/2 Pathological/morphological atrophy brain brain volume decrease, striatal
44 9-11 wks n/d 2: 8898202 R6/2 behavior motor organism hindlimb clasping (dyskinesia)
45 5-6 wks 10+ wks 20: 10864968 R6/2 E-phys changes synaptic plasticity brain/hippocampus CA1 / increased LTD LTD, long-term depression
46 26 wks 52 wks 26: 12812983 YAC 128 behavior motor organism decreased open field activity (dancenight)
47 4 wks 8 wks 25: 16137562 R6/2 behavior motor organism decreased rearing activity
48 4 wks n/d 9: 9267033 R6/2 Pathological/morphological atrophy brain brain weight loss
49 11-15 wks n/d 5: 16127709 R6/2 behavior motor organism sustained flexure of forelimbs and hindlimbs
50 10.7-12.1 wks n/d 16: 11746372 R6/2 E-phys changes basic membrane properties brain/striatum/medium-sized spiny neurons reduced membrane capacitance
51 13 wks 13 wks 26: 12812983 YAC 128 behavior motor organism increased movements
52 12 wks 15 wks 1: 15579164 R6/2 Pathological/morphological aggregates skeletal muscle nuclear inclusions
53 day 1 12.9 wks 5: 16127709 R6/2 Pathological/morphological aggregates brain/cortex htt-positive aggregates
54 52 wks n/d 26: 12812983 YAC 128 Pathological/morphological atrophy brain/cortex cortex volume
55 8 wks n/d 25: 16137562 R6/2 behavior motor organism rotorod
56 8.5 wks n/d 23: 10575040 R6/2 behavior cognitive organism two-choice swim tank, retention (visual learning)
57 4.5 -5.5 wks 8.5- 9.5 wks 25: 16137562 R6/2 behavior motor organism decreased running wheel activity (night)
58 5-6 wks 13-14 wks 7: 10191337 R6/2 behavior motor organism rotorod
59 3-4 wks 5-7 wks 19: 12574425 R6/2 E-phys changes action potential properties brain/striatum/medium-sized spiny neurons large-amplitude events
60 4 wks 12 wks 6: 10369868 R6/2 Pathological/morphological aggregates brain/cortex ENNI ENNI, extranuclear inclusion; EM48 ab
61 12-16 wks n/d 1: 15579164 R6/2 E-phys changes Non-CNS changes neuromuscular junction increased EPP failure EPP, end-plate potential
62 7 wks n/d 25: 16137562 R6/2 behavior motor organism grip strength
63 12 wks 15 wks 1: 15579164 R6/2 Pathological/morphological atrophy skeletal muscle atrophy
64 5-7 wks 11 wks 3: 16087879 R6/2 Pathological/morphological atrophy organism weight loss
65 n/d 7 wks 20: 10864968 R6/2 behavior cognitive organism Morris Water Maze (spatial learning)
66 n/d 13 wks 10: 11353291 R6/2 Pathological/morphological aggregates brain/striatum ENNI ENNI, extranuclear inclusion, most pronounced in large interneurons
67 10.7-12.1 wks n/d 14: 11746372 R6/2 Pathological/morphological neurodegeneration brain/striatum medium-sized spiny neurons/smaller somata
68 8-9 wks 13-14 wks 7: 10191337 R6/2 behavior motor organism beam walking
69 8.6 wks 13.9 wks 5: 16127709 R6/2 Pathological/morphological general organism survival Less than 2% of the mice died prematurely through cfonstant seizure activity as early as 8.6 wks.
70 n/d 10 wks 10: 11353291 R6/2 Pathological/morphological aggregates brain/hippocampus DG ENNI ENNI, extranuclear inclusion; also seen in lacunosum moleculare; immunogold anti ubiquitin ab
71 3.5 wks 6-9 wks 11: 12115678 R6/2 Pathological/morphological aggregates brain/cortex NII NII, neuronal intranuclear inclusion; anti-ubiquitin ab, four mouse monoclonal abs, and polyclonal EM48 were used.
72 5.3-6.0 wks 11.6-14.4 wks 13: 11731527 R6/2 E-phys changes basic membrane properties brain/striatum/medium-sized spiny neurons increased input resistance
73 10 wks 13 wks 7: 10191337 R6/2 Pathological/morphological atrophy organism weight loss
74 n/d 7- 10 wks 10: 11353291 R6/2 Pathological/morphological aggregates brain/thalamus NII NII, neuronal intranuclear inclusion; onset not well documented, immunogold anti-ubiquitin ab
75 11.6-14.4 wks n/d 13: 11731527 R6/2 E-phys changes action potential properties brain/striatum increased stimulation required to induce EPSPs EPSP, excitatory postsynaptic potential
76 5-6 wks 10-13 wks 7: 10191337 R6/2 behavior motor organism swimming tank (straight line)
77 3.5 wks n/d 23: 10575040 R6/2 behavior cognitive organism Morris Water Maze (spatial learning)
78 11.6-14.4 wks n/d 13: 11731527 R6/2 E-phys changes basic membrane properties brain/striatum/medium-sized spiny neurons decreased membrane time constants
79 10.7-12.1 wks n/d 16: 11746372 R6/2 E-phys changes basic membrane properties brain/striatum/medium-sized spiny neurons decreased membrane time constants
80 3 wks 6-8 wks 4: 16034568 R6/2 Pathological/morphological aggregates pancreas beta cells/ubiquitin-positive inclusions
81 4 wks 12 wks 5: 16127709 R6/2 behavior motor organism prolonged helicoptering of hindlimbs
82 n/d 12-13 wks 7: 10191337 R6/2 behavior motor organism epileptic seizures
83 n/d 6 wks 22: 10829080 R6/2 E-phys changes receptor/neurotransmitter responses brain/striatum/medium-sized spiny neurons reduced dopaminergic modulation of voltage-gated calcium current Lack of dopaminergic channel modulation was due to defects in the D1/cAMP/PKA/DARPP-32 signaling cascade.
84 6.5 wks 8.5-11.5 wks 23: 10575040 R6/2 behavior cognitive organism two-choice swim tank (reversal learning)
85 9.9 wks n/d 5: 16127709 R6/2 Pathological/morphological atrophy organism weight loss, female Age specified represents onset of significant weight loss.
86 9-11 wks n/d 2: 8898202 R6/2 behavior motor organism tremor
87 52 wks 78 wks 26: 12812983 YAC 128 Pathological/morphological aggregates brain/striatum htt-positive aggregates Nuclear htt staining (antibody EM48) seen as “microaggregates” at 12 mo. Nuclear inclusions seen at 18 mo.
88 5-7 wks n/d 19: 12574425 R6/2 E-phys changes receptor/neurotransmitter responses brain/striatum/medium-sized spiny neurons Glu synaptic activity changes
89 6 wks 12 wks 15: 10196370 R6/2 Pathological/morphological atrophy skeletal muscle atrophy quadriceps and soleus muscle
90 10 wks n/d 5: 16127709 R6/2 behavior motor organism increased movements
91 n/d 11-15 wks 18: 15625098 R6/2 E-phys changes potassium channels brain/striatum/medium-sized spiny neurons reduced outward potassium current density
92 11.6-14.4 wks n/d 13: 11731527 R6/2 E-phys changes action potential properties brain/striatum/medium-sized spiny neurons alterations in the ability to generate trains of APs
93 4 wks n/d 25: 16137562 R6/2 behavior motor organism decreased climbing activity
94 8 wks 8 wks 24: 16111888 R6/2 behavior motor organism rotorod Some drop off in rotorod performance seen at 4 wks
95 6 wks 12 wks 15: 10196370 R6/2 Pathological/morphological aggregates skeletal muscle nuclear inclusions
96 day 1 12 .9 wks 5: 16127709 R6/2 Pathological/morphological aggregates brain/striatum htt-positive aggregates
97 5.0-6.5 wks 10.7-12.1 wks 16: 11746372 R6/2 E-phys changes basic membrane properties brain/striatum/medium-sized spiny neurons increased input resistance
98 8-12 wks 8-12 wks 1: 15579164 R6/2 E-phys changes Non-CNS changes neuromuscular junction increased EPP decay time EPP, end-plate potential
99 9 wks 14 wks 4: 16034568 R6/2 Pathological/morphological metabolic organism diabetes Earliest onset of glucosuria was 9.3 wks. Glucose intolerance was detected at 9 wks. Aggressive behavioral testing (swimming) accelerated the onset of diabetes.
100 6.4 wks 12 wks 5: 16127709 R6/2 Pathological/morphological neurodegeneration brain/striatum progressive neurodegeneration
101 12 + wks 15 wks 1: 15579164 R6/2 Pathological/morphological neurodegeneration neuromuscular junction AChR defects onset not well documented
102 6 wks 12 wks 15: 10196370 R6/2 Pathological/morphological atrophy kidney atrophy
103 12.9 wks n/d 5: 16127709 R6/2 Pathological/morphological neurodegeneration brain/striatum increased reactive astrogliosis
104 5-7 wks 11-15 wks 18: 15625098 R6/2 E-phys changes basic membrane properties brain/striatum/medium-sized spiny neurons increased input resistance
105 3 wks 10 wks 10: 11353291 R6/2 Pathological/morphological aggregates brain/cortex NII NII, neuronal intranuclear inclusion; onset not well documented, immunogold anti-ubiquitin ab
106 4 wks 8 wks 15: 10196370 R6/2 Pathological/morphological atrophy testes atrophy
107 5-7 wks 9-14 wks 17: 15505789 R6/2 E-phys changes basic membrane properties brain/striatum/medium-sized spiny neurons reduced membrane capacitance The change at 5-7 wks was observed, but not shown to be significant
108 n/d 11-15 wks 18: 15625098 R6/2 E-phys changes basic membrane properties brain/striatum/medium-sized spiny neurons depolarized RMPs
109 16 wks 20 wks 1: 15579164 R6/2 Pathological/morphological general organism survival
110 4.5-5.5 wks n/d 25: 16137562 R6/2 behavior motor organism increased anxiety (light/dark box) Anxiety was only observed in male R6/2 mice at 4.5-5.5 wks.
111 5-6.5 wks 10.7-12.1 wks 16: 11746372 R6/2 E-phys changes receptor/neurotransmitter responses brain/striatum/medium-sized spiny neurons increased NMDA response NMDA-induced peak currents and current densities were higher for in a “responsive” subpopulation of R6/2 mice neurons vs WT mouse neurons
112 8 wks 12-13 wks 7: 10191337 R6/2 behavior motor organism irregular gait
113 n/d 52 wks 26: 12812983 YAC 128 Pathological/morphological neurodegeneration brain/striatum striatal neurons/ smaller somata 18% decrease in neuronal area.
114 52 wks 78 wks 26: 12812983 YAC 128 Pathological/morphological aggregates brain/striatum NII Nuclear htt staining (antibody EM48) seen as “microaggregates” at 12 mo. Nuclear inclusions seen at 18 mo.
115 7 wks 10 wks 10: 11353291 R6/2 Pathological/morphological aggregates brain/hippocampus CA3 NII NII, neuronal intranuclear inclusion; onset not well documented, immunogold anti ubiquitin ab
116 5 wks n/d 23: 10575040 R6/2 behavior cognitive organism T-maze (alternation learning)
117 14- 14.5 wks 16 wks 12: 10869421 R6/2 Pathological/morphological neurodegeneration brain/cortex progressive neurodegeneration Dark neurons
118 9 wks n/d 5: 16127709 R6/2 behavior motor organism grip strength, hindlimb
119 n/d 3 wks 10: 11353291 R6/2 Pathological/morphological aggregates brain/hippocampus CA1 NII NII, neuronal intranuclear inclusion; onset not well documented; immunogold anti-ubiquitin ab
120 n/d 12.5 wks 7: 10191337 R6/2 behavior motor organism acoustic startle/prepulse inhibition
121 4 wks n/d 25: 16137562 R6/2 behavior motor organism decreased open field activity (night)
122 14 – 14.5 wks 16 wks 12: 10869421 R6/2 Pathological/morphological neurodegeneration brain/striatum progressive neurodegeneration Dark neurons
123 5.3-6.0 wks 11.6-14.4 wks 13: 11731527 R6/2 E-phys changes action potential properties brain/striatum/medium-sized spiny neurons decreased rheobase rheobase, stimulus intensity to evoke action potentials
124 n/d 12 + wks 20: 10864968 R6/2 E-phys changes synaptic plasticity brain/hippocampus DG / reduced LTP onset not well documented, DG, dentate gyrus
125 8 wks n/d 15: 10196370 R6/2 Pathological/morphological aggregates liver nuclear inclusions
126 8.5 – 9.5 wks n/d 25: 16137562 R6/2 behavior motor organism decreased running wheel activity (day)
127 12 + wks 15 wks 1: 15579164 R6/2 Pathological/morphological neurodegeneration neuromuscular junction nerve sprouting defects onset not well documented
128 5 wks 13 wks 5: 16127709 R6/2 behavior motor organism rotorod
129 39 wks 52 wks 26: 12812983 YAC 128 Pathological/morphological neurodegeneration brain/striatum decrease in striatal neuronal number 15% decrease at 12 mo. Decrease of total neuronal and MSN counts at 9 mo not significant, but indicate a trend.
130 n/d 10 wks 10: 11353291 R6/2 Pathological/morphological aggregates brain/cortex ENNI ENNI, extranuclear inclusion; immunogold anti-ubiquitin ab
131 11.6-14.4 wks n/d 13: 11731527 R6/2 Pathological/morphological neurodegeneration brain/striatum medium-sized spiny neurons/dendritic deficits
132 14 – 14.5 wks 16 wks 12: 10869421 R6/2 Pathological/morphological neurodegeneration brain/cerebellum progressive neurodegeneration Dark neurons
133 6 wks 8 wks 6: 10369868 R6/2 Pathological/morphological atrophy brain brain weight loss
134 9-11 wks n/d 2: 8898202 R6/2 behavior motor organism excessive grooming/ hyperactivity
135 8 wks 12 wks 6: 10369868 R6/2 Pathological/morphological atrophy organism weight loss
136 10.7-12.1 wks n/d 16: 11746372 R6/2 E-phys changes calcium channels brain/striatum/medium-sized spiny neurons reduced calcium current density neurons from pre-symptomatic mice (5-6.5 wks) had slightly higher calcium current density
137 n/d 10.86 wks 3: 16087879 R6/2 Pathological/morphological general organism survival
138 3.5 wks 6-9 wks 11: 12115678 R6/2 Pathological/morphological aggregates brain/striatum NII NII, neuronal intranuclear inclusion; anti-ubiquitin ab, four mouse monoclonal abs, and polyclonal EM48 were used.
139 n/d 6 wks 22: 10829080 R6/2 E-phys changes receptor/neurotransmitter responses brain/striatum/medium-sized spiny neurons reduced dopaminergic modulation of AMPA current Lack of dopaminergic channel modulation was due to defects in the D1/cAMP/PKA/DARPP-32 signaling cascade.
140 8 wks n/d 7: 10191337 R6/2 behavior motor organism hindlimb clasping (dyskinesia)
141 8.9 wks n/d 5: 16127709 R6/2 Pathological/morphological atrophy organism weight loss, male Age specified represents onset of significant weight loss.
142 12 wks 15 wks 1: 15579164 R6/2 Pathological/morphological neurodegeneration neuromuscular junction neurofilament abnormalities
143 26 wks 39-52 wks 26: 12812983 YAC 128 behavior motor organism rotorod Rotorod deficits highly correlated with striatal neuronal cell loss.
144 4 wks 12 wks 6: 10369868 R6/2 Pathological/morphological aggregates brain/striatum ENNI ENNI, extranuclear inclusion; EM48 ab
145 n/d 15-16 wks 4: 16034568 R6/2 Pathological/morphological general organism survival
146 3 wks 4.5 wks 10: 11353291 R6/2 Pathological/morphological aggregates brain/striatum NII NII, neuronal intranuclear inclusion; immunogold anti-ubiquitin ab
147 4.5 – 5.5 wks 8.5 -9.5 wks 25: 16137562 R6/2 behavior motor organism increased breaks from running wheel (dark)
Experiments
Experiment # Citation PubMed ID Author Name Author Email
exp-1 Ribchester, et al, Eur. J. Neurosci, 20, 3092-3114, 2004 15579164 A. Jennifer Morton ajm41@cam.ac.uk
exp-2 Mangiarini, et al., Cell, 87, 493-506, 1996 8898202 Gillian Bates gillian.bates@genetics.kcl.ac.uk
exp-3 Nguyen, et al., PNAS 102, 11840-11845, 2005 16087879 Stephen M. Massa massa3@itsa.ucsf.edu
exp-4 Hunt and Morton, Exp Brain Res, 2005 16034568 A. Jennifer Morton ajm41@cam.ac.uk
exp-5 Stack, et al., J. Comparative Neurology 490:354-370, 2005 16127709 Robert J. Ferrante rjferr@bu.edu
exp-6 Li, et al., Hum Mol Genetics, 8, 1227-1236, 1999 10369868 Xiao-Jiang Li xiaoli@genetics.emory.edu
exp-7 Carter, et al., J. Neurosci, 19, 3248-57, 1999 10191337 A. Jennifer Morton ajm41@cam.ac.uk
exp-8 Hurlbert, et al., Diabetes, 48, 649-651, 1999 10078572 Curt R. Freed curt.freed@uchsc.edu
exp-9 Davies et al., Cell, 90, 537-548, 1997 9267033 S. W. Davies s.w.davies@ucl.ac.uk
exp-10 Morton, et al, J. Neurocytology, 29, 679-702, 2000 11353291 A. Jennifer Morton ajm41@cam.ac.uk
exp-11 Meade, et al., J. Comp Neurol. 449, 241-69, 2002 12115678 Christopher Meade cmeade@utmem.edu
exp-12 Turmaine, et al., PNAS 97, 8093-8097, 2000 10869421 Stephen W. Davies s.w.davies@ucl.ac.uk
exp-13 Klapstein, et al, J. Neurophysiol, 86, 2667-2677, 2001 11731527 Michael S. Levine mlevine@mednet.ucla.edu
exp-14 Cepeda, et al., J. Neurosci Research, 66, 525-539, 2001 11746372 Michael S. Levine mlevine@mednet.ucla.edu
exp-15 Sathasivam, et al, Hum. Mol. Genetics, 8, 813-822, 1999 10196370 Gillian Bates gillian.bates@genetics.kcl.ac.uk
exp-16 Cepeda, et al, J Neurosci Res., 66, 525-39, 2001 11746372 Michael S. Levine mlevine@mednet.ucla.edu
exp-17 Cepeda, et al., J. Neurosci Res., 78, 855-867, 2004 15505789 Michael S. Levine mlevine@mednet.ucla.edu
exp-18 Ariano, et al., J. Neurophysiol. 93, 2565-2574, 2005 15625098 C. Cepeda ccepeda@mednet.ucla.edu
exp-19 Cepeda, et al., J. Neuroscience, 23, 961-969, 2003 12574425 Michael S. Levine mlevine@mednet.ucla.edu
exp-20 Murphy, et al, J. Neurosci., 20, 5115-5123, 2000 10864968 Kerry P. S. J. Murphy k.murphy@open.ac.uk
exp-21 Levine, et al., J Neurosci Res., 58:515-532, 1999 10533044 Michael S. Levine mlevine@mednet.ucla.edu
exp-22 Bibb, et al., PNAS 97, 6809-6814 10829080 bibbj@rockvax.rockefeller.edu
exp-23 Lione, et al., J. Neurosci., 19, 10428-10437, 1999 10575040 Lisa A. Lione Lisa.Lione@wl.com
exp-24 Hockly et al., Neurobiology of Disease, 2005 16111888 Gillian Bates gillian.bates@genetics.kcl.ac.uk
exp-25 Hickey, et al., Neurobiology of Disease 20, 1- 11, 2005 16137562 M. -F Chesselet mchesselet@mednet.ucla.edu
exp-26 Slow, et. Al, HMG 2003, Vol 12, 1555-1567 12812983 Michael R. Hayden mrh@cmmt.ubc.ca

Copyright © 2001-2024, Institute for Systems Biology
Privacy Statement | Copyright, Warranty & Disclaimer
Last updated  Contact Us